The 2020 Access & Savings Report Reinforces The Importance Of Reforming Our U.S. Healthcare System To Increase Competition, Save Billions IN CASE YOU MISSED IT: This week, the Association for Accessible Medicines (AAM) – a member of the Coalition Against Patent Abuse (CAPA) – released their annual report on generic drug and biosimilars access and […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA), a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others, issued a statement today supporting a new study entitled, “The Growing Power of Biotech Monopolies Threatens Affordable Care” by Avik Roy and Gregg Girvan of the Foundation for Research on Equal Opportunity (FREOPP) which […]

Continue Reading

IN CASE YOU MISSED IT: A new study by Alex Brill of Matrix Global Advisors (MGA) and commissioned by the Coalition for Affordable Prescription Drugs (CAPD) offers the latest evidence that pharma’s delay tactics are costing Americans billions of dollars. These challenges are especially important as the federal government faces unprecedented debt and millions of Americans are […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, the Coalition Against Patent Abuse applauded a recent decision by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing practices by the big drug companies.   “CAPA applauds today’s announcement by the […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA), a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others, applauded a decision today by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing […]

Continue Reading